Objectives. The aim was to study lymphocyte subsets and circulating cytokines at diagnosis of PMR and after tocilizumab monotherapy.
Introduction
The pathophysiology of PMR remains unclear. Recent work has demonstrated low circulating B-cell counts in active PMR followed by a return to normal after CS therapy [1] . Several lines of evidence indicate that IL-6 is the pro-inflammatory cytokine that varies most widely in PMR, increasing in active disease and declining after CS therapy [2, 3] , suggesting a pathophysiological role for IL-6 in the disease. Based on this evidence, tocilizumab, a mAb to the IL-6 receptor (IL-6R), was used successfully in several patients with refractory PMR [4] . Furthermore, in patients with newly diagnosed PMR enrolled in two open-label phase 2 studies, tocilizumab therapy induced clinical disease remission [5, 6] . The biological effects accompanying the clinical efficacy of tocilizumab are unknown.
Our aim was to compare the distribution of lymphocyte subsets and circulating concentrations of pro-inflammatory and anti-inflammatory cytokines, including IL-6, in patients with PMR, both at diagnosis and after tocilizumab therapy, as well as in age-and sex-matched controls.
Methods

Patients, controls and intervention
Eighteen patients with untreated PMR participating in the Tolerance and Efficacy of tocilizumab iN pOlymyalgia Rheumatica (TENOR) study (registered at ClinicalTrials.gov, NCT01713842) at the Brest University Hospital, France, were included. Inclusion and exclusion criteria for TENOR are described elsewhere [5] . Tocilizumab was given as three 8 mg/kg i.v. infusions, at baseline and at 4 and 8 weeks (W) later, without glucocorticoids. From W12 to W24, patients received low-dose prednisone (0.15 mg/kg/day, tapered according to a predefined schedule). Disease activity was measured by the PMR activity score (PMR-AS) [7] , which includes CRP and physician and patient visual analog scale scores for disease activity, morning stiffness and shoulder elevation. The primary end point of the TENOR study was PMR-AS <10 at W12. Early response was defined as PMR-AS <10 at W4. Blood samples were collected at baseline, W2 and W12 (i.e. after tocilizumab monotherapy) then at W24 (after prednisone therapy).
We recruited 18 age-and sex-matched controls among patients visiting our rheumatology department for mechanical pain, with no infectious, auto-immune or malignant disease. All patients gave their written informed consent according to the Declaration of Helsinki. This study was approved by an ethics committee (CPP Ouest VI).
Lymphocyte subset analysis and cytokine assays 
Results
Among the 18 patients included, 7 were women (likewise for controls). Mean age at inclusion was, respectively, 68 (7) and 66 (11) years for patients and controls (P = 0.8).
Mean BMI was, respectively, 28 (1) and 29 (1) kg/m 2 for patients and controls (P = 0.3). Serum concentrations of CRP were, respectively, 82 (16) and 5 (2) mg/l for patients and controls (P < 0.01). All patients not only fulfilled Chuang's criteria but also fulfilled the 2012 provisional ACR/EULAR criteria, received a definite diagnosis of PMR according to the evaluating physician, and underwent a systematic evaluation to rule out alternative diagnoses. After 2 years of follow-up, none of the PMR diagnosis was invalidated. In all 18 patients, PMR-AS was <10 at W12 [5] . Of note, as CRP measurements are not interpretable after tocilizumab, the detailed analysis of individual PMR-AS components showed that all clinical measures were also significantly improved during the TENOR study [5] . In eight patients, there was an early response (PMR-AS <10 at W4). No patient required CSs because of an increase of disease activity (assessed by the PMR-AS) before W12, and no patient experienced a disease flare until the end of the study (W24). 1B) were also significantly lower in patients compared with controls. At baseline (i.e. in active untreated patients), despite this relative B-cell lymphopenia compared with controls, both total B-cell (Fig. 1C) and switched memory B-cell (r = 0.5, P = 0.02) counts were positively correlated with disease activity evaluated by the PMR-AS. This observation could be explained by a hyperinflammatory state in some patients with a dramatic increase of acute-phase reactants, as the serum concentration of CRP was also positively correlated with the B-cell count (r = 0.5, P = 0.03).
Tocilizumab therapy corrects B-cell subset distribution
Absolute total lymphocyte and CD19 + B-cell counts increased progressively and significantly between baseline and W12 during tocilizumab monotherapy ( Fig. 1D and supplementary Table S2 , available at Rheumatology Online). This correction of the baseline B-cell lymphopenia was chiefly ascribable to increases in IgD + CD27 À naïve B cells and IgD À CD27 + switched memory B cells, which were the most severely decreased subsets at baseline compared with controls ( Fig. 1D and E) . Other B-cell subsets also increased between baseline and W12, but to a lesser extent (supplementary Table S2 , available at Rheumatology Online). Only patients with an early clinical response (PMR-AS <10 at W4) had significant increases in total B cells and switched memory B cells at W2 (Fig. 1F) .
Increased serum IL-6 is correlated with disease activity in PMR patients
The cytokine array in two patients and two controls revealed a large increase in IL-6 and moderate increases in IL-1b and CD40-ligand (CD40-L) concentrations in patients at baseline compared with controls. IL-6, IL-1b, TNF-a and CD40-L concentrations in the patients were lower at W12 after tocilizumab therapy than at baseline ( Fig. 2A) .
As the variations were clearly largest for IL-6, we measured serum IL-6 concentrations in all controls and patients at baseline and W12, by ELISA. Serum IL-10 was also assayed as a negative marker. The mean IL-6 concentration was nearly 10-fold higher in the patients [112 (19) vs 13 (3) pg/ml in controls, P < 0.01; Fig. 2B ], whereas IL-10 concentrations were similar [30 (10) and 19 (4) pg/ ml, respectively; P = 0.1, data not shown]. The IL-6 concentration was correlated with baseline PMR-AS (Fig. 2C ) and CRP concentration (r = 0.7, P = 0.003).
In the patients, the mean IL-6 concentration was not significantly lower at W12 vs baseline (Fig. 2D) . However, the change in IL-6 concentrations from baseline to W12 varied widely across patients. In nine patients with marked baseline IL-6 elevation, IL-6 concentrations dropped between baseline and W12, from 171 (17) to 76 (10) pg/ml (P < 0.01). The remaining eight patients had lower baseline IL-6 concentrations, followed by a slight increase in IL-6 by W12, from 40 (15) to 72 (13) pg/ml (P < 0.01). Interestingly, the nine patients whose IL-6 concentrations decreased had significant increases in (P < 0.01); whereas the trend for B-cell count increase we observed in the patients whose IL-6 concentrations increased was not significant (Fig. 2E and F) .
FIG. 1 B-Cell lymphopenia and B-cell subset distribution abnormalities in patients with PMR improved after tocilizumab therapy Lymphocyte counts in patients with PMR (black bars) and controls (white bars). (A) Lymphocytes and subsets at baseline in patients and controls (mean ± S.D.). (B) B-Cell subsets in patients and controls (mean and S.E.M.). (C) Correlation between B-cell (CD19 + ) count and PMR activity score (PMR-AS) at baseline (slope was calculated using linear regression). (D and E) Changes in B-cell subsets over time in the patients (mean and S.E.M.). (F) Changes in B-cell (CD19
Discussion
In patients with PMR, peripheral B-cell lymphopenia and abnormal B-cell subset distribution were associated with disease activity and were corrected after tocilizumab monotherapy. This effect was associated with the pro-inflammatory cytokine IL-6, because it occurred mainly in those patients whose serum IL-6 concentrations decreased after tocilizumab therapy. Van der Geest et al. (E and F) Two groups of patients were defined according to IL-6 evolution: decrease vs increase in IL-6 serum concentration between baseline and week 12 (E, left and right panels, respectively). Evolution of B-cell counts between baseline and week 12 in these two groups (F, left and right panels, respectively).
between ESR and B-cell concentrations after remission was induced by CSs [1], whereas we observed here a negative correlation between baseline B-cell counts and PMR-AS (and CRP) in active untreated patients, illustrating the heterogeneity of biological findings in PMR patients. Our finding of similar changes after tocilizumab monotherapy suggests that correction of the B-cell abnormalities may be attributable to a decrease in disease activity rather than to CS exposure and that inflammation and IL-6 may be responsible for the alterations in B-cell distribution. In contrast, in patients with RA, tocilizumab specifically modulated IgD + CD27 + unswitched memory B cells [8] and NK cells [9] and seemed to induce a decrease in memory B-cell populations [10] . These data underline the pathophysiological differences between these diseases in which B-cell subsets are disturbed [11] , and the fact that most patients with RA received tocilizumab after several lines of therapies and concomitantly with MTX, whereas in the present study PMR patients received tocilizumab as a first-line monotherapy. Several facts support a pathophysiological role for IL-6 in PMR [12] . IL-6 is increased in serum [13] , muscles [14] and SF [15] from patients with PMR. A polymorphism in the IL-6 promoter is associated with PMR symptoms in patients with GCA [16] . Finally, serum IL-6 concentrations are associated with disease activity [13] and decrease after CS therapy [2] . In our study, serum IL-6 was correlated with disease activity at onset but, although all patients achieved remission after tocilizumab [5] , serum IL-6 decreased only in the subgroup with the highest baseline IL-6 concentrations. Interestingly, in healthy volunteers, who received tocilizumab in a phase 1 study, and patients with RA or Castleman disease, serum IL-6 increased significantly after tocilizumab therapy, probably owing to inhibition of IL-6R-mediated clearance of IL-6 [17] . It is important to note that serum concentrations of IL-6 are different according to the disease considered; in RA, patients presented an increase in IL-6 from 58 to 93 pg/ml, and in healthy volunteers from 3 to 9 pg/ml [17] . In our study, patients with a moderately increased baseline IL-6 concentration acted in a similar manner to patients with RA, with an increase from 40 to 72 pg/ml, probably corresponding to the inhibition of IL-6 clearance as already described. But for the other patients (with very high baseline IL-6 concentrations), this increase is counterbalanced by the important decrease attributable to the control of inflammation and, probably, the decrease of IL-6 production by immune system cells.
IL-6 plays an important role in B-cell terminal differentiation [18] . It has also been reported that IL-6 could play a role in regulatory B-cell induction [19] and in the germinal centre through follicular Th cells [20] . We can assume that IL-6, by playing a role in B-cell terminal differentiation, can disturb B-cell homeostasis. Further studies are needed to unravel the precise mechanism of this interplay.
Finally, an early increase in CD19 + B cells at W2 was associated with an early clinical response. Thus, the CD19 + B-cell count might hold promise for predicting the time to tocilizumab response. As observed in the TENOR study, tocilizumab had a longer time to action compared with CSs, and predicting the time to response may therefore prove helpful. Given that all patients experienced an improvement of disease activity, we were not able to analyse predictive factors of the disease course during the time of follow-up.
Our study provides the first data on changes in lymphocyte populations and pro-inflammatory cytokines during tocilizumab therapy in patients with PMR, driving hypotheses regarding the pathophysiology of the disease.
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